Medline ® Abstract for Reference 41
of 'Direct-acting antivirals for the treatment of hepatitis C virus infection'
Poordad F, Pol S, Asatryan A, et al. MAGELLAN-1, Part 2: Glecaprevir/pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Presented at the 52nd Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, The Netherlands, April 19-23, 2017.
no abstract available